Shares of 4basebio PLC (LON:4BB – Get Free Report) dropped 2.1% on Thursday . The company traded as low as GBX 1,185 ($14.67) and last traded at GBX 1,185 ($14.67). Approximately 3,034 shares changed hands during trading, a decline of 31% from the average daily volume of 4,379 shares. The stock had previously closed at GBX 1,210 ($14.98).
4basebio Stock Down 2.1 %
The firm has a 50-day moving average of GBX 1,251.16 and a two-hundred day moving average of GBX 1,376.71. The stock has a market capitalization of £151.80 million, a price-to-earnings ratio of -1,519.23 and a beta of 1.09. The company has a quick ratio of 3.52, a current ratio of 2.73 and a debt-to-equity ratio of 201.47.
Insider Activity
In related news, insider Heikki Lanckriet bought 46,500 shares of the firm’s stock in a transaction on Friday, November 15th. The stock was bought at an average price of GBX 1,325 ($16.40) per share, with a total value of £616,125 ($762,625.32). 68.44% of the stock is owned by corporate insiders.
About 4basebio
4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.
Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.
Featured Stories
- Five stocks we like better than 4basebio
- What Does Downgrade Mean in Investing?
- 3 Legacy Tech Companies Reemerging as AI Leaders
- EV Stocks and How to Profit from Them
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for 4basebio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4basebio and related companies with MarketBeat.com's FREE daily email newsletter.